You are viewing the site in preview mode

Skip to main content
Fig. 1 | BMC Endocrine Disorders

Fig. 1

From: Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN)

Fig. 1

Study design. aThe planned EOST visit was on Week 33 (Day 225) for subjects in lanreotide autogel group and on Week 32 (Day 221 or Day 223 depending on dosing regimen) for subjects in lanreotide 40 mg PR group. EOST/EW, End of Study/ Early Withdrawal Visit; GH, growth hormone; IGF-1, insulin-like growth factor-1; PK, pharmacokinetics; PR, prolonged release

Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us